Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease

Author:

Roe Matthew T.1,Harrington Robert A.1,Prosper Danielle M.1,Pieper Karen S.1,Bhatt Deepak L.1,Lincoff A. Michael1,Simoons Maarten L.1,Akkerhuis Martijn1,Ohman E. Magnus1,Kitt Michael M.1,Vahanian Alec1,Ruzyllo Witold1,Karsch Karl1,Califf Robert M.1,Topol Eric J.1

Affiliation:

1. From the Duke Clinical Research Institute (M.T.R., R.A.H., K.S.P., E.M.O., R.M.C.), Durham, NC; the Cleveland Clinic Foundation (D.M.P., D.L.B, A.M.L., E.J.T), Cleveland, OH; the Thoraxcenter (M.L.S., M.A.), Erasmus University, Rotterdam, the Netherlands; COR Therapeutics, Inc (M.M.K.), South San Francisco, Calif; Hospital Tenon (A.V.), Paris, France; the National Institute of Cardiology (W.R.), Warsaw, Poland; and Eberhard Karls University (K.K.), Tubingen, Germany.

Abstract

Background —A proportion of patients who present with suspected acute coronary syndrome (ACS) are found to have insignificant coronary artery disease (CAD) during coronary angiography, but these patients have not been well characterized. Methods and Results —Of the 5767 patients with non–ST-segment elevation ACS who were enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial and who underwent in-hospital angiography, 88% had significant CAD (any stenosis >50%), 6% had mild CAD (any stenosis >0% to ≤50%), and 6% had no CAD (no stenosis identified). The frequency of death or nonfatal myocardial infarction at 30 days was reduced with eptifibatide treatment in patients with significant CAD (18.3% versus 15.6% for placebo, P =0.006) but not in those with mild CAD (6.6% versus 5.4%, P =0.62) and with no CAD (3.0% versus 1.2%, P =0.28). We identified independent baseline predictors of insignificant CAD (mild or no CAD) and used them to develop a simple predictive nomogram of the probability of insignificant CAD for use at hospital presentation. This nomogram was validated in a separate population of patients with non–ST-segment elevation ACS. Conclusions —Patients with suspected ACS found to have insignificant CAD have a low risk of adverse outcomes, do not appear to benefit from treatment with eptifibatide, and can be predicted with a simple nomogram drawn from baseline characteristics. Because patients with significant CAD appear to have an enhanced benefit from eptifibatide treatment, the predictive nomogram developed can be used to determine indications for glycoprotein IIb/IIIa blockade.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 172 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3